Brian D. Evavold, PhD

Chief, Division of Microbiology and Immunology


Lab Website


  • English

Academic Information

  • Departments: Pathology - Professor
  • Divisions: Microbiology and Immunology

Academic Office Information

  • 801-585-9689
  • Emma Eccles Jones Research Building
    15 North Medical Drive East, Room: Room 5200B
    Salt Lake City, UT 84112


Research Statement

My research centers on how antigen recognition by T cells determines cell phenotype, fate, and outcome of the adaptive immune response. Understanding the mechanisms driving T cell activation provides novel insight into the basis of autoimmune disease and effective response to infections.

Education History

Type School Degree
Postdoctoral Fellowship Washington University
T Cell Responses to Altered Peptide Ligands
Postdoctoral Fellow
Doctoral Training University of Chicago
T Cell Responses
Undergraduate St. Olaf College
Chemistry, Biology

Global Impact


Description Country
Evavold BD. Altered peptide ligands for the T cell receptor. Cardiff University-Immunology Seminar Series, Cardiff, Wales, United Kingdom United Kingdom
Evavold BD. T cell response to Altered peptide ligands. Autumn British Transplantation Society Meeting, London, England, United Kingdom United Kingdom
Evavold BD. Variant peptide ligands for the TCR. Immunology Seminar Series, King’s College London, London, England, United Kingdom United Kingdom
Evavold BD. Affinity of myelin specific T cells. 5th Aegean Autoimmune Conference, Crete, Greece Greece
Evavold BD. 2D T cell affinity of myelin reactive T cells. Department of Microbiology Seminar Series, University of British Columbia, Vancouver, British Columbia, Canada Canada
Evavold BD. 2D affinity of CD4+ T cells. Cardiff University, London, Wales, United Kingdom United Kingdom
Evavold BD. Frequency and affinity of CD4+ Tregs. University of Edinburgh, Edinburgh, Scotland, United Kingdom United Kingdom
Evavold BD. 2D frequency and affinity of myelin specific Tregs. Stochastic, statistical and computational approaches to Immunology, Edinburgh, Scotland, United Kingdom United Kingdom
Evavold BD. Affinity of myelin specific. 6th Aegean Autoimmune Conference, Corfu, Greece Greece
Evavold BD. Frequency and 2D affinity of CD4 T cells. Lausanne Cancer Institute, Lausanne, Switzerland Switzerland
Evavold BD. 2D affinity of CD4 T cells. MRC Immunology Seminar, Mill Hill, London, United Kingdom United Kingdom
Evavold BD. T cell activation; the force awakens. Bridge Gaps & Crossroads Symposium, student invited speaker, University of Vienna, Vienna, Austria Austria

Selected Publications

Journal Article

  1. Sibener LV, Fernandes RA, Kolawole EM, Carbone CB, Liu F, McAffee D, Birnbaum ME, Yang X, Su LF, Yu W, Dong S, Gee MH, Jude KM, Davis MM, Groves JT, Goddard WA 3rd, Heath JR, Evavold BD, Vale RD, Garcia KC (2018 Jul 26). Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding. Cell, 174(3), 672-687.e27.
  2. Andargachew R, Martinez RJ, Kolawole EM, Evavold BD (2018 Jul 1). CD4 T Cell Affinity Diversity Is Equally Maintained during Acute and Chronic Infection. J Immunol, 201(1), 19-30.
  3. Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI (2018 Feb). Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunol Immunother, 67(2), 311-325.
  4. Sanecka A, Yoshida N, Kolawole EM, Patel H, Evavold BD, Frickel EM (2018). T Cell Receptor-Major Histocompatibility Complex Interaction Strength Defines Trafficking and CD103(+) Memory Status of CD8 T Cells in the Brain. Front Immunol, 9, 1290.
  5. Blanchfield L, Sabatino JJ Jr, Lawrence L, Evavold BD (2017 Oct 15). NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease. J Immunol, 199(8), 2680-2691.
  6. Cole DK, Fuller A, Dolton G, Zervoudi E, Legut M, Miles K, Blanchfield L, Madura F, Holland CJ, Bulek AM, Bridgeman JS, Miles JJ, Schauenburg AJA, Beck K, Evavold BD, Rizkallah PJ, Sewell AK (2017). Dual Molecular Mechanisms Govern Escape at Immunodominant HLA A2-Restricted HIV Epitope. Front Immunol, 8, 1503.
  7. Baker BM, Evavold BD (2017 Jan). MHC Bias by T Cell Receptors: Genetic Evidence for MHC and TCR Coevolution. Trends Immunol, 38(1), 2-4.
  8. Bally AP, Tang Y, Lee JT, Barwick BG, Martinez R, Evavold BD, Boss JM (2017 Jan 1). Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory. J Immunol, 198(1), 205-217.
  9. Martinez RJ, Andargachew R, Martinez HA, Evavold BD (2016 Dec 15). Low-affinity CD4+ T cells are major responders in the primary immune response. Nat Commun, 7, 13848.
  10. Pennati A, Ng S, Wu Y, Murphy JR, Deng J, Rangaraju S, Asress S, Blanchfield JL, Evavold B, Galipeau J (2016 Dec 14). Regulatory B Cells Induce Formation of IL-10-Expressing T Cells in Mice with Autoimmune Neuroinflammation. J Neurosci, 36(50), 12598-12610.
  11. Martinez RJ, Morris AB, Neeld DK, Evavold BD (2016 Sep). Targeted loss of SHP1 in murine thymocytes dampens TCR signaling late in selection. Eur J Immunol, 46(9), 2103-10.
  12. Ma VP, Liu Y, Blanchfield L, Su H, Evavold BD, Salaita K (2016 Jul 13). Ratiometric Tension Probes for Mapping Receptor Forces and Clustering at Intermembrane Junctions. Nano Lett, 16(7), 4552-9.
  13. Liu Y, Blanchfield L, Ma VP, Andargachew R, Galior K, Liu Z, Evavold B, Salaita K (2016 May 17). DNA-based nanoparticle tension sensors reveal that T-cell receptors transmit defined pN forces to their antigens for enhanced fidelity. Proc Natl Acad Sci U S A, 113(20), 5610-5.
  14. Krummey SM, Martinez RJ, Andargachew R, Liu D, Wagener M, Kohlmeier JE, Evavold BD, Larsen CP, Ford ML (2016 Mar 15). Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity. J Immunol, 196(6), 2838-46.
  15. Merkenschlager J, Ploquin MJ, Eksmond U, Andargachew R, Thorborn G, Filby A, Pepper M, Evavold B, Kassiotis G (2016 Jan 05). Stepwise B-cell-dependent expansion of T helper clonotypes diversifies the T-cell response. Nat Commun, 7, 10281.
  16. Shorter SK, Schnell FJ, McMaster SR, Pinelli DF, Andargachew R, Evavold BD (2016). Viral Escape Mutant Epitope Maintains TCR Affinity for Antigen yet Curtails CD8 T Cell Responses. PLoS ONE, 11(2), e0149582.
  17. Hood JD, Zarnitsyna VI, Zhu C, Evavold BD (2015 Nov 1). Regulatory and T Effector Cells Have Overlapping Low to High Ranges in TCR Affinities for Self during Demyelinating Disease. J Immunol, 195(9), 4162-70.
  18. Hong J, Persaud SP, Horvath S, Allen PM, Evavold BD, Zhu C (2015 Oct 15). Force-Regulated In Situ TCR-Peptide-Bound MHC Class II Kinetics Determine Functions of CD4+ T Cells. J Immunol, 195(8), 3557-64.
  19. Frost EL, Kersh AE, Evavold BD, Lukacher AE (2015 Oct 15). Cutting Edge: Resident Memory CD8 T Cells Express High-Affinity TCRs. J Immunol, 195(8), 3520-4.
  20. Martinez RJ, Neeld DK, Evavold BD (2015 Sep). Identification of T cell clones without the need for sequencing. J Immunol Methods, 424, 28-31.
  21. Kersh AE, Edwards LJ, Evavold BD (2014 Nov 1). Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread. J Immunol, 193(9), 4429-38.
  22. Bettini M, Blanchfield L, Castellaw A, Zhang Q, Nakayama M, Smeltzer MP, Zhang H, Hogquist KA, Evavold BD, Vignali DA (2014 Jul 15). TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential. J Immunol, 193(2), 571-9.
  23. Pryshchep S, Zarnitsyna VI, Hong J, Evavold BD, Zhu C (2014 Jul 1). Accumulation of serial forces on TCR and CD8 frequently applied by agonist antigenic peptides embedded in MHC molecules triggers calcium in T cells. J Immunol, 193(1), 68-76.
  24. Liu B, Chen W, Evavold BD, Zhu C (2014 Apr 10). Accumulation of dynamic catch bonds between TCR and agonist peptide-MHC triggers T cell signaling. Cell, 157(2), 357-68.
  25. Edwards LJ, Evavold BD (2013 Aug). Destabilization of peptide:MHC interaction induces IL-2 resistant anergy in diabetogenic T cells. J Autoimmun, 44, 82-90.
  26. Hofstetter AR, Evavold BD, Lukacher AE (2013 Feb). Peptide immunization elicits polyomavirus-specific MHC class ib-restricted CD8 T cells in MHC class ia allogeneic mice. Viral Immunol, 26(1), 109-13.
  27. Blanchfield JL, Shorter SK, Evavold BD (2013). Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology. Front Immunol, 4, 170.
  28. Salinas GF, Krausz S, Dontje W, Evavold BD, Tak PP, Baeten DL, Reedquist KA (2012 Sep 15). Sustained Rap1 activation in autoantigen-specific T lymphocytes attenuates experimental autoimmune encephalomyelitis. J Neuroimmunol, 250(1-2), 35-43.
  29. Zinzow-Kramer WM, Long AB, Youngblood BA, Rosenthal KM, Butler R, Mohammed AU, Skountzou I, Ahmed R, Evavold BD, Boss JM (2012 Jun). CIITA promoter I CARD-deficient mice express functional MHC class II genes in myeloid and lymphoid compartments. Genes Immun, 13(4), 299-310.
  30. Schubert DA, Gordo S, Sabatino JJ Jr, Vardhana S, Gagnon E, Sethi DK, Seth NP, Choudhuri K, Reijonen H, Nepom GT, Evavold BD, Dustin ML, Wucherpfennig KW (2012 Feb 13). Self-reactive human CD4 T cell clones form unusual immunological synapses. J Exp Med, 209(2), 335-52.
  31. Edwards LJ, Zarnitsyna VI, Hood JD, Evavold BD, Zhu C (2012). Insights into T cell recognition of antigen: significance of two-dimensional kinetic parameters. Front Immunol, 3, 86.
  32. Rosenthal KM, Edwards LJ, Sabatino JJ Jr, Hood JD, Wasserman HA, Zhu C, Evavold BD (2012). Low 2-dimensional CD4 T cell receptor affinity for myelin sets in motion delayed response kinetics. PLoS ONE, 7(3), e32562.
  33. Jiang N, Huang J, Edwards LJ, Liu B, Zhang Y, Beal CD, Evavold BD, Zhu C (2011 Jan 28). Two-stage cooperative T cell receptor-peptide major histocompatibility complex-CD8 trimolecular interactions amplify antigen discrimination. Immunity, 34(1), 13-23.
  34. Sabatino JJ Jr, Huang J, Zhu C, Evavold BD (2011 Jan 17). High prevalence of low affinity peptide-MHC II tetramer-negative effectors during polyclonal CD4+ T cell responses. J Exp Med, 208(1), 81-90.
  35. Evavold BD, Allen PM (2011 Jan 1). Pillars article: separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 1991. 252: 1308-1310. J Immunol, 186(1), 9-12.
  36. Huang J, Zarnitsyna VI, Liu B, Edwards LJ, Jiang N, Evavold BD, Zhu C (2010 Apr 8). The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. Nature, 464(7290), 932-6.
  37. Edwards LJ, Evavold BD (2010). A unique unresponsive CD4+ T cell phenotype post TCR antagonism. Cell Immunol, 261(1), 64-8.
  38. Bettini M, Rosenthal K, Evavold BD (2009 Aug 18). Pathogenic MOG-reactive CD8+ T cells require MOG-reactive CD4+ T cells for sustained CNS inflammation during chronic EAE. J Neuroimmunol, 213(1-2), 60-8.
  39. Manicassamy S, Ravindran R, Deng J, Oluoch H, Denning TL, Kasturi SP, Rosenthal KM, Evavold BD, Pulendran B (2009 Apr). Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med, 15(4), 401-9.
  40. Schnell FJ, Alberts-Grill N, Evavold BD (2009 Feb 15). CD8+ T cell responses to a viral escape mutant epitope: active suppression via altered SHP-1 activity. J Immunol, 182(4), 1829-35.
  41. Wasserman HA, Beal CD, Zhang Y, Jiang N, Zhu C, Evavold BD (2008 Nov 15). MHC variant peptide-mediated anergy of encephalitogenic T cells requires SHP-1. J Immunol, 181(10), 6843-9.
  42. Jones DS, Reichardt P, Ford ML, Edwards LJ, Evavold BD (2008 Aug 1). TCR antagonism by peptide requires high TCR expression. J Immunol, 181(3), 1760-6.
  43. Wasserman HA, Evavold BD (2008 Jun 1). Induction of anergy by antibody blockade of TCR in myelin oligodendrocyte glycoprotein-specific cells. J Immunol, 180(11), 7259-64.
  44. Sabatino JJ Jr, Shires J, Altman JD, Ford ML, Evavold BD (2008 Apr 1). Loss of IFN-gamma enables the expansion of autoreactive CD4+ T cells to induce experimental autoimmune encephalomyelitis by a nonencephalitogenic myelin variant antigen. J Immunol, 180(7), 4451-7.
  45. Huang J, Edwards LJ, Evavold BD, Zhu C (2007 Dec 1). Kinetics of MHC-CD8 interaction at the T cell membrane. J Immunol, 179(11), 7653-62.
  46. Ford ML, Evavold BD (2006 Mar). Modulation of MOG 37-50-specific CD8+ T cell activation and expansion by CD43. Cell Immunol, 240(1), 53-61.
  47. Kumar S, Skeen MJ, Adiri Y, Yoon H, Vezys VD, Lukacher AE, Evavold BD, Ziegler HK, Boss JM (2005 Oct). A cytokine promoter/yellow fluorescent protein reporter transgene serves as an early activation marker of lymphocyte subsets. Cell Immunol, 237(2), 131-40.
  48. Margot CD, Ford ML, Evavold BD (2005 Mar 15). Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid protein 139-151. J Immunol, 174(6), 3352-8.
  49. Ford ML, Evavold BD (2005 Jan). Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. Eur J Immunol, 35(1), 76-85.
  50. Ford ML, Evavold BD (2004 Feb). An MHC anchor-substituted analog of myelin oligodendrocyte glycoprotein 35-55 induces IFN-gamma and autoantibodies in the absence of experimental autoimmune encephalomyelitis and optic neuritis. Eur J Immunol, 34(2), 388-97.
  51. Ryan KR, McNeil LK, Dao C, Jensen PE, Evavold BD (2004 Jan). Modification of peptide interaction with MHC creates TCR partial agonists. Cell Immunol, 227(1), 70-8.
  52. Ford ML, Onami TM, Sperling AI, Ahmed R, Evavold BD (2003 Dec 15). CD43 modulates severity and onset of experimental autoimmune encephalomyelitis. J Immunol, 171(12), 6527-33.
  53. Ford ML, Evavold BD (2003 Aug 1). Regulation of polyclonal T cell responses by an MHC anchor-substituted variant of myelin oligodendrocyte glycoprotein 35-55. J Immunol, 171(3), 1247-54.
  54. Kilgore NE, Carter JD, Lorenz U, Evavold BD (2003 May 15). Cutting edge: dependence of TCR antagonism on Src homology 2 domain-containing protein tyrosine phosphatase activity. J Immunol, 170(10), 4891-5.
  55. McNeil LK, Evavold BD (2003 Feb 1). TCR reserve: a novel principle of CD4 T cell activation by weak ligands. J Immunol, 170(3), 1224-30.
  56. McNeil LK, Evavold BD (2002 Apr 2). Dissociation of peripheral T cell responses from thymocyte negative selection by weak agonists supports a spare receptor model of T cell activation. Proc Natl Acad Sci U S A, 99(7), 4520-5.
  57. Robertson JM, Jensen PE, Evavold BD (2000 May 1). DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J Immunol, 164(9), 4706-12.
  58. Robertson JM, Evavold BD (1999 Aug 15). Cutting edge: dueling TCRs: peptide antagonism of CD4+ T cells with dual antigen specificities. J Immunol, 163(4), 1750-4.
  59. Sourdive DJ, Murali-Krishna K, Altman JD, Zajac AJ, Whitmire JK, Pannetier C, Kourilsky P, Evavold B, Sette A, Ahmed R (1998 Jul 6). Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med, 188(1), 71-82.
  60. Ryan KR, Evavold BD (1998 Jan 5). Persistence of peptide-induced CD4+ T cell anergy in vitro. J Exp Med, 187(1), 89-96.
  61. Weber DA, Evavold BD, Jensen PE (1996 Oct 25). Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science, 274(5287), 618-20.
  62. Evavold BD, Sloan-Lancaster J, Wilson KJ, Rothbard JB, Allen PM (1995 Jun). Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. Immunity, 2(6), 655-63.
  63. Hsu BL, Evavold BD, Allen PM (1995 Feb 1). Modulation of T cell development by an endogenous altered peptide ligand. J Exp Med, 181(2), 805-10.
  64. Sloan-Lancaster J, Evavold BD, Allen PM (1994 Oct 1). Th2 cell clonal anergy as a consequence of partial activation. J Exp Med, 180(4), 1195-205.
  65. Evavold BD, Sloan-Lancaster J, Allen PM (1994 Mar 15). Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand. Proc Natl Acad Sci U S A, 91(6), 2300-4.
  66. Hagerty DT, Evavold BD, Allen PM (1994 Mar). Regulation of the costimulator B7, not class II major histocompatibility complex, restricts the ability of murine kidney tubule cells to stimulate CD4+ T cells. J Clin Invest, 93(3), 1208-15.
  67. Sloan-Lancaster J, Evavold BD, Allen PM (1993 May 13). Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature, 363(6425), 156-9.
  68. Evavold BD, Sloan-Lancaster J, Hsu BL, Allen PM (1993 Apr 15). Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J Immunol, 150(8 Pt 1), 3131-40.
  69. Evavold BD, Williams SG, Hsu BL, Buus S, Allen PM (1992 Jan 15). Complete dissection of the Hb(64-76) determinant using T helper 1, T helper 2 clones, and T cell hybridomas. J Immunol, 148(2), 347-53.
  70. Ditzian-Kadanoff R, Parks L, Evavold B, Quintans J, Swartz TJ (1991 Dec). Stimulation of peripheral blood T cells by an activated T-cell line: a novel human autologous T-T lymphocyte reaction. Scand J Immunol, 34(6), 713-9.
  71. Hagerty DT, Evavold BD, Allen PM (1991 Nov 15). The processing and presentation of the self-antigen hemoglobin. Self-reactivity can be limited by antigen availability and costimulator expression. J Immunol, 147(10), 3282-8.
  72. Evavold BD, Allen PM (1991 May 31). Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science, 252(5010), 1308-10.
  73. Tiegs SL, Evavold BD, Yokoyama A, Stec S, Quintans J, Rowley D (1990 Oct). Delayed antigen presentation by epidermal Langerhans cells to cloned T h1 and T h2 cells. J Invest Dermatol, 95(4), 446-9.
  74. Evavold BD, Quintans J (1989 Sep 15). Accessory cell function of Th2 clones. J Immunol, 143(6), 1784-9.
  75. Yokoyama A, Evavold B, Dunn DE, Quintans J (1989 May). Production of IL-2 and IFN by TH2 clones. Immunol Lett, 21(2), 119-25.
  76. Evavold BD, Yokoyama A, Hirsch R, Bluestone JA, Quintans J (1989). T helper 2 (Th2) but not Th1 clones co-stimulate resting T cells in the presence of anti-CD3 monoclonal antibody. Int Immunol, 1(4), 443-9.
  77. Quintans J, Yokoyama A, Evavold B, Hirsch R, Mayforth RD (1989). Direct activation of murine resting T cells by con A or anti-CD3 Ig. J Mol Cell Immunol, 4(4), 225-35; discussion 235-7.
  78. Swartz TJ, Evavold B, Suzuki H, Yokoyama A, Quintans J (1988 Jul). Antigenicity of passively acquired major histocompatibility antigens on T cells. Transplantation, 46(1), 137-43.
  79. Suzuki H, Evavold B, Swartz TJ, Latta SL, Quintans J (1986). The syngeneic T-T lymphocyte reaction (STTLR). I. Induction of primary T anti-T cell proliferative responses in T cell cultures stimulated with self- and antigen-reactive T cells. J Mol Cell Immunol, 2(6), 331-44.


  1. Martinez RJ, Evavold BD (2015). Lower Affinity T Cells are Critical Components and Active Participants of the Immune Response. [Review]. Front Immunol, 6, 468.
  2. Zarnitsyna VI, Evavold BD, Schoettle LN, Blattman JN, Antia R (2013 Dec 26). Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire. [Review]. Front Immunol, 4, 485.
  3. Zhu C, Jiang N, Huang J, Zarnitsyna VI, Evavold BD (2013 Jan). Insights from in situ analysis of TCR-pMHC recognition: response of an interaction network. [Review]. Immunol Rev, 251(1), 49-64.
  4. Edwards LJ, Evavold BD (2011 May). T cell recognition of weak ligands: roles of signaling, receptor number, and affinity. [Review]. Immunol Res, 50(1), 39-48.
  5. Sabatino JJ Jr, Rosenthal KM, Evavold BD (2010 Jun). Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE. [Review]. J Neuroimmune Pharmacol, 5(2), 176-88.
  6. Ford ML, Evavold BD (2004 Feb). Degenerate recognition of T cell epitopes: impact of T cell receptor reserve and stability of peptide:MHC complexes. [Review]. Mol Immunol, 40(14-15), 1019-25.
  7. Kilgore NE, Ford ML, Margot CD, Jones DS, Reichardt P, Evavold BD (2004). Defining the parameters necessary for T-cell recognition of ligands that vary in potency. [Review]. Immunol Res, 29(1-3), 29-40.
  8. Stojiljkovic I, Evavold BD, Kumar V (2001 Feb). Antimicrobial properties of porphyrins. [Review]. Expert Opin Investig Drugs, 10(2), 309-20.
  9. Evavold BD, Sloan-Lancaster J, Allen PM (1993 Dec). Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. [Review]. Immunol Today, 14(12), 602-9.
  10. Evavold BD, Allen PM (1992). Dissection of the Hb(64-76) determinant reveals that the T cell receptor may have the capacity to differentially signal. [Review]. Adv Exp Med Biol, 323, 17-21.
  11. Evavold BD, Williams SG, Chen JS, Allen PM (1991 Jul). T cell inducing determinants contain a hierarchy of residues contacting the T cell receptor. [Review]. Semin Immunol, 3(4), 225-9.


  1. Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI (2018 Feb). Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Cancer Immunol Immunother (67(2), p. 327). Germany.